Last reviewed 2026-04-22 · How we verify

TPO

TPO is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating the thrombopoietin receptor on hematopoietic stem cells.

TPO is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating the thrombopoietin receptor on hematopoietic stem cells. Used for Immune thrombocytopenia (ITP), Thrombocytopenia associated with chronic liver disease.

At a glance

Mechanism of action

TPO (thrombopoietin) mimetics work by activating the c-Mpl receptor, which is the physiological receptor for endogenous thrombopoietin. This activation promotes megakaryocyte differentiation and platelet production in the bone marrow. The drug is used to increase platelet counts in patients with thrombocytopenia.

Approved indications

• Immune thrombocytopenia (ITP)
• Thrombocytopenia associated with chronic liver disease

Common side effects

• Headache
• Diarrhea
• Fatigue
• Thromboembolic events

Key clinical trials

• Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
• Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence (PHASE2)
• rhTPO Dose Escalation vs Eltrombopag Switch in ITP (NA)
• Avatrombopag vs. Placebo for CIT in GI Malignancies (PHASE2)
• Research of Predictive Factors to Immune Thrombopenic Purpura (NA)
• Dysregulation of the Soluble α-Klotho-FGF23 Axis in Hashimoto's Thyroiditis: A Case-Control Study
• A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure (PHASE1, PHASE2)
• Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.